Who are General sevoflurane anaesthesia's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Sevoflurane or Propofol, Sevorane (sevoflurane, Abbott), Sevoflurane inhalant product, Inhaled sedation with sevoflurane, Sevoflurane Inhalational Induction and Maintenance.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/general-sevoflurane-anaesthesia.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

General sevoflurane anaesthesia — Competitive Intelligence Brief

General sevoflurane anaesthesia (General sevoflurane anaesthesia) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Volatile anesthetic agent. Area: Anesthesiology.

phase 3 Volatile anesthetic agent GABA-A receptor, NMDA glutamate receptor Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

General sevoflurane anaesthesia (General sevoflurane anaesthesia) — KK Women's and Children's Hospital. Sevoflurane is a volatile anesthetic that depresses central nervous system activity by enhancing inhibitory GABA neurotransmission and inhibiting excitatory glutamate signaling.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
General sevoflurane anaesthesia TARGET	General sevoflurane anaesthesia	KK Women's and Children's Hospital	phase 3	Volatile anesthetic agent	GABA-A receptor, NMDA glutamate receptor
Sevoflurane or Propofol	Sevoflurane or Propofol	University Health Network, Toronto	marketed	General anesthetic	GABA-A receptor, NMDA glutamate receptor
Sevorane (sevoflurane, Abbott)	Sevorane (sevoflurane, Abbott)	Medical University of Gdansk	marketed	Volatile anesthetic	GABA-A receptor, NMDA glutamate receptor
Sevoflurane inhalant product	Sevoflurane inhalant product	Sunnybrook Health Sciences Centre	marketed	Volatile inhalational anesthetic	GABA-A receptor, NMDA glutamate receptor
Inhaled sedation with sevoflurane	Inhaled sedation with sevoflurane	University Hospital, Clermont-Ferrand	phase 3	Volatile anesthetic	GABA-A receptor, NMDA glutamate receptor
Sevoflurane Inhalational Induction and Maintenance	Sevoflurane Inhalational Induction and Maintenance	Abbott	marketed	Volatile anesthetic agent	GABA receptors, NMDA receptors, potassium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Volatile anesthetic agent class)

Abbott · 1 drug in this class
KK Women's and Children's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). General sevoflurane anaesthesia — Competitive Intelligence Brief. https://druglandscape.com/ci/general-sevoflurane-anaesthesia. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab